In response to a Congressional request, an ad hoc committee of the National Academies of Sciences, Engineering, and Medicine will conduct a study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union, including:
- Flexibilities, authorities, or mechanisms available to regulators in the United States and the European Union applicable to rare diseases or conditions
No specific eligibility criteria are mentioned, implying broad accessibility for engagement.